Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections ( CROI ) . Investigators concluded that the drug was well tolerated and effective against HIV , including strains with gag polymorphisms . Phase 2b studies are currently ongoing in early 2016 . It appears that development of BMS-955176 has been terminated .
Conference on Retroviruses and Opportunistic Infections
Conference on Retroviruses and Opportunistic Infections
BMS-955176